Delivered 38% year-over-year net revenue growth in H1 2026, driven by strong recurring revenues and expansion into 14 new markets. Reaffirmed full-year guidance with robust momentum across dermatology, Medtech AI, and CDMO, supported by a debt-free balance sheet and over EUR 200 million in cash.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.